Karen S. Lynch - May 3, 2023 Form 4 Insider Report for CVS HEALTH Corp (CVS)

Role
President and CEO, Director
Signature
/s/ Karen S. Lynch
Stock symbol
CVS
Transactions as of
May 3, 2023
Transactions value $
$976,567
Form type
4
Date filed
5/5/2023, 08:27 AM
Previous filing
Apr 4, 2023
Next filing
Feb 14, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CVS Common Stock (By Trust) Purchase $977K +14K +3.35% $69.75 431K May 3, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CVS Stock Appreciation Rights 193K May 3, 2023 Common Stock 193K $45.91 Direct F1
holding CVS Stock Appreciation Rights 94K May 3, 2023 Common Stock 94K $37.91 Direct F2
holding CVS Stock Option 242K May 3, 2023 Common Stock 242K $54.19 Direct F3
holding CVS Stock Option 211K May 3, 2023 Common Stock 211K $58.34 Direct F4, F5
holding CVS Stock Option 225K May 3, 2023 Common Stock 225K $74.30 Direct F6
holding CVS Stock Option 172K May 3, 2023 Common Stock 172K $101.09 Direct F7
holding CVS Stock Option 245K May 3, 2023 Common Stock 245K $74.31 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents unvested Aetna Inc. Stock Appreciation Rights ("SARs") granted under the Aetna Plan on February 17, 2017 that were converted into CVS Health SARs pursuant to the terms of the CVS/Aetna Merger Agreement. These SARs vest in two substantially equal annual installments beginning on February 17, 2019.
F2 Represents unvested SARs granted under the Aetna Plan on February 19, 2016 that were converted into CVS Health SARs pursuant to the terms of the CVS/Aetna Merger Agreement. These SARs vested on February 19, 2019.
F3 Option became exercisable in four equal annual installments, commencing 4/1/2020.
F4 The number of shares subject to the option were calculated using a 30-day average price.
F5 Option became exercisable in four equal installments, commencing 4/1/2021.
F6 Option became exercisable in four equal installments, commencing 4/1/2022.
F7 Option became exercisable in four equal installments, commencing 4/1/2023.
F8 Option becomes exercisable in four equal annual installments, commencing 4/1/2024.